CompletedPhase 3NCT03746522
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Studying Alström syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Principal Investigator
- David Meeker, MDRhythm Pharmaceuticals, Inc.
- Intervention
- Setmelanotide(drug)
- Enrollment
- 52 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2018 – 2021
Study locations (12)
- Wr-McCr, Llc, San Diego, California, United States
- UMMS Baystate Health; BAYSTATE MEDICAL CENTER; Baystate Children's Specialty Center, Springfield, Massachusetts, United States
- Columbia University Center, New York, New York, United States
- M3 Wake Research, Raleigh, North Carolina, United States
- University of Tennessee Health Science Center, Memphis, Tennessee, United States
- Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States
- Alberta Health Services, Edmonton, Alberta, Canada
- Sorbonne University, Hôpital de la Pitié-Salpêtrière, Paris, France
- Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France
- UPR Medical Sciences Campus, Rio Piedras, Puerto Rico
- Universidad Autónoma de Madrid University Hospital Niño, Madrid, Spain
- St. Thomas Hospital, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03746522 on ClinicalTrials.govOther trials for Alström syndrome
Additional recruiting or active studies for the same condition.